O-GlcNAc transferase as an oncogenic regulator in hematologic malignancies
Identifying which blood cancer patients have a specific genetic marker could help doctors choose targeted therapies that block the protein driving their disease.
- Lab
- Preclinical
- Early trials
- Late trials
- In practice
Oncofetal chondroitin sulfate on tumor-derived extracellular vesicles
A placental protein reappearing on cancer particles in blood offers a new way to detect multiple cancer types from a simple blood test.
Promising but preliminaryArtificial intelligence-based diagnostic model for identifying…
AI can now identify a dangerous brain tumor mutation without invasive biopsies, helping doctors plan better treatment strategies upfront.
Novel or significantly improved treatmentEfficient discovery of an agonistic anti-OX40 nanobody by…
A new engineered immune booster paired with CAR-T cells shows stronger anti-tumor effects in early studies, potentially improving cell therapy outcomes.
Novel or significantly improved treatmentBispecific ANXA2/CD147 CAR-T cell therapy for osteosarcoma
Targeting two cancer proteins simultaneously with CAR-T cells addresses why single-target approaches fail, offering hope for solid tumors like osteosarcoma.